Revenue 142,254 million yen (YoY +9.0%), Operating Income 12,745 million yen (YoY +22.0%), Ordinary Income 10,093 million yen, Net Income Attributable to Owners of Parent for the interim period 6,866 million yen. Achieved the first-half plan largely, supported by trends at Towa Pharmaceutical and Sansho Pharmaceutical. Will closely monitor developments in Europe and the U.S. in the second half. Increases in R&D expenses and SG&A impacted results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4553-20261111-03.pdf","jir_short_summary":"Revenue 142,254 million yen (YoY +9.0%), Operating Income 12,745 million yen (YoY +22.0%), Ordinary Income 10,093 million yen, Net Income Attributable to Owners of Parent for the interim period 6,866 million yen. Achieved the first-half plan largely, supported by trends at Towa Pharmaceutical and Sansho Pharmaceutical. Will closely monitor developments in Europe and the U.S. in the second half. Increases in R&D expenses and SG&A impacted results.","jir_summary":"### Summary of Results\nFor the second quarter of the fiscal year ending March 2027, consolidated revenue increased year-on-year, and despite increases in SG&A and R&D expenses, operating income rose significantly. Contributions from overseas segments and improved profitability in domestic segments supported near achievement of the first-half plan.\n\n### Outlook and Points to Note\nThe second half is likely to be sensitive to market trends in Europe and the United States, with the sales progress of the new application business and the status of license revenue being particularly important. The impact of non-cash items such as goodwill amortization continues, and attention should be paid to overall profit levels.","jir_financial_highlights":"Revenue: 142,254 (YoY +9.0%)\nOperating Income: 12,745 (YoY +22.0%)\nOrdinary Income: 10,093 (YoY -15.7%)\nNet Income Attributable to Owners of Parent (interim): 6,866 (YoY -16.4%)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #Earnings, #PharmaceuticalCompany","jir_key_figures":"Revenue: 142,254 million yen\nOperating Income: 12,745 million yen\nOrdinary Income: 10,093 million yen","jir_meta_title":"Towa Pharmaceutical Co., Ltd. \u2014 FY2027 Q2 Financial Summary | Revenue 142,254 million yen (+9.0%)","jir_meta_description":"Consolidated financial summary for Towa Pharmaceutical Co., Ltd. for FY2027 Q2. Revenue up 9.0% YoY and operating income up 22.0%. Analysis of segment trends and outlook for the second half.","jir_og_title":"Towa Pharmaceutical Co., Ltd. \u2014 Financial Summary: Revenue 142,254 million yen, Operating Income 12,745 million yen","jir_og_description":"FY2027 Q2 consolidated results for Towa Pharmaceutical Co., Ltd.: revenue up 9.0% YoY and operating income up 22.0%. Key outlook points and highlights summarized.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"27\/3 2Q Actual\\\",\\\"26\/3 2Q Actual\\\",\\\"27\/3 First-Half Plan\\\",\\\"27\/3 Full-Year Plan\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[142254,130476,145700,304000],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"27\/3 2Q Actual\\\",\\\"26\/3 2Q Actual\\\",\\\"27\/3 First-Half Plan\\\",\\\"27\/3 Full-Year Plan\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[12745,10443,12700,32000],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Towa Pharmaceutical and others\\\",\\\"Sansho Pharmaceutical and others\\\",\\\"Towa INT\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[98443+0,13034,31134],\\\"backgroundColor\\\":[\\\"#4caf50\\\",\\\"#81c784\\\",\\\"#64b5f6\\\"]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Gross Margin \/ SG&A Ratio Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"27\/3 2Q\\\",\\\"26\/3 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Margin\\\",\\\"data\\\":[36.2,36.2],\\\"backgroundColor\\\":\\\"#66bb6a\\\"},{\\\"label\\\":\\\"SG&A Ratio\\\",\\\"data\\\":[25.3,25.5],\\\"backgroundColor\\\":\\\"#42a5f5\\\"}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Comparison of Guidance and Actuals\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"27\/3 2Q Actual\\\",\\\"26\/3 2Q Actual\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[142254,130476],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Full-Year Plan\\\",\\\"data\\\":[304000,304000],\\\"borderColor\\\":\\\"#ff9800\\\",\\\"fill\\\":false}]}}\"}]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149183","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n